Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective

Autores
Talevi, Alan
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.
Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Departamento de Ciencias Biológicas. Cátedra de Química Medicinal; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
DESIGNED MULTIPLE LIGANDS
DRUG DESIGN
DRUG REPOSITIONING
DRUG RESISTANCE
GENE PROFILE
LOCK AND KEY PARADIGM
MULTI-TARGET AGENTS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/53786
Acceder
id CONICETDig_797532507eeb60c8f667647243795bc6
oai_identifier_str oai:ri.conicet.gov.ar:11336/53786
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspectiveTalevi, AlanDESIGNED MULTIPLE LIGANDSDRUG DESIGNDRUG REPOSITIONINGDRUG RESISTANCEGENE PROFILELOCK AND KEY PARADIGMMULTI-TARGET AGENTShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Departamento de Ciencias Biológicas. Cátedra de Química Medicinal; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFrontiers Research Foundation2015-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/53786Talevi, Alan; Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective; Frontiers Research Foundation; Frontiers in Pharmacology; 6; SEP; 9-2015; 1-71663-9812CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fphar.2015.00205info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fphar.2015.00205/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:28:32Zoai:ri.conicet.gov.ar:11336/53786instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:28:33.136CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
title Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
spellingShingle Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
Talevi, Alan
DESIGNED MULTIPLE LIGANDS
DRUG DESIGN
DRUG REPOSITIONING
DRUG RESISTANCE
GENE PROFILE
LOCK AND KEY PARADIGM
MULTI-TARGET AGENTS
title_short Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
title_full Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
title_fullStr Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
title_full_unstemmed Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
title_sort Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
dc.creator.none.fl_str_mv Talevi, Alan
author Talevi, Alan
author_facet Talevi, Alan
author_role author
dc.subject.none.fl_str_mv DESIGNED MULTIPLE LIGANDS
DRUG DESIGN
DRUG REPOSITIONING
DRUG RESISTANCE
GENE PROFILE
LOCK AND KEY PARADIGM
MULTI-TARGET AGENTS
topic DESIGNED MULTIPLE LIGANDS
DRUG DESIGN
DRUG REPOSITIONING
DRUG RESISTANCE
GENE PROFILE
LOCK AND KEY PARADIGM
MULTI-TARGET AGENTS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.
Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Departamento de Ciencias Biológicas. Cátedra de Química Medicinal; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.
publishDate 2015
dc.date.none.fl_str_mv 2015-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/53786
Talevi, Alan; Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective; Frontiers Research Foundation; Frontiers in Pharmacology; 6; SEP; 9-2015; 1-7
1663-9812
CONICET Digital
CONICET
url http://hdl.handle.net/11336/53786
identifier_str_mv Talevi, Alan; Multi-target pharmacology: Possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective; Frontiers Research Foundation; Frontiers in Pharmacology; 6; SEP; 9-2015; 1-7
1663-9812
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3389/fphar.2015.00205
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fphar.2015.00205/full
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Research Foundation
publisher.none.fl_str_mv Frontiers Research Foundation
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781864450195456
score 12.982451

Publicaciones similares